296 results on '"Lenting, Peter J."'
Search Results
2. Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosis
3. How unique structural adaptations support and coordinate the complex function of von Willebrand factor
4. Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in von Willebrand disease murine models
5. A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD
6. Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis
7. Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia
8. Structure and dynamics of the platelet integrin-binding C4 domain of von Willebrand factor
9. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
10. Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions
11. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A
12. Macrophage receptor SR-AI is crucial to maintain normal plasma levels of coagulation factor X
13. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends
14. A nanobody against the von Willebrand factor A3-domain detects ADAMTS13-induced proteolysis in congenital & acquired VWD
15. A FVIII-Mimetic Bispecific Antibody with an Embedded Self-Regulation Mechanism Reduces the Risk of Prothrombotic Events for the Treatment of Haemophilia a
16. Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B–associated thrombocytopenia
17. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant
18. Mutations in the A3 domain of Von Willebrand factor inducing combined qualitative and quantitative defects in the protein
19. A murine model to characterize the antithrombotic effect of molecules targeting human von Willebrand factor
20. Macrophage LRP1 contributes to the clearance of von Willebrand factor
21. Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B
22. A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF
23. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients
24. von Willebrand disease: what does the future hold?
25. Impaired adhesion of neutrophils expressing Slc44a2/HNA-3b to VWF protects against NETosis under venous shear rates
26. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo
27. Altered thrombus formation in von Willebrand factor–deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa
28. β2-Glycoprotein I inhibits von Willebrand factor–dependent platelet adhesion and aggregation
29. A hemophilia A mouse model for the in vivo assessment of emicizumab function
30. Cofactor and Cofactor Mimetics
31. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B
32. LDL-receptor–related protein regulates β2-integrin–mediated leukocyte adhesion
33. Von Willebrand factor C1C2 domain is involved in platelet adhesion to polymerized fibrin at high shear rate
34. A factor VIII–nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation
35. Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor–related protein deficiency
36. Functional mapping of anti–factor IX inhibitors developed in patients with severe hemophilia B
37. Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor–related protein
38. Von Willebrand factor: how unique structural adaptations support and coordinate its complex function
39. VWF clearance: it’s glycomplicated
40. Von Willebrand Factor Interaction with FVIII: Development of Long Acting FVIII Therapies
41. Plasmin-Cleaved Von Willebrand Factor As a Biomarker for Microvascular Thrombosis
42. Mechanisms and Therapeutic Modulation of the Bleeding Tendency in Genetically-Engineered Von Willebrand Disease Type 2B Mice
43. Platelet Desialylation Is a Novel Mechanism of Thrombocytopenia during Mechanical Circulatory Assistance
44. Von Willebrand Factor As a Biological Sensor of Blood Flow in Percutaneous Cardiac Procedures
45. The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma
46. Expression of a structurally constrained von Willebrand factor variant triggers acute thrombotic thrombocytopenic purpura in mice
47. Platelet von Willebrand factor: sweet resistance
48. Determinants of von Willebrand Factor Function
49. A nanobody against the von Willebrand factor A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired von Willebrand disease
50. SHEARiO, fast lane to oxidized VWF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.